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Introduction {#sec1}
============

Typical examples of subepidermal blistering skin diseases are bullous pemphigoid and epidermolysis bullosa acquisita, the latter disease having both an inflammatory and a noninflammatory (mechanobullous) form ([@bib20], [@bib25]). Both bullous pemphigoid and epidermolysis bullosa acquisita are caused by autoimmune targeting of components of the dermal-epidermal junction and are triggered by autoantibodies against the hemidesmosomal proteins BP230/BP180 or the dermal anchoring fibril protein type VII collagen (C7), respectively ([@bib3], [@bib43], [@bib49]). In the case of bullous pemphigoid and the inflammatory form of epidermolysis bullosa acquisita, this leads to local inflammation and disruption of the dermal-epidermal junction, mediated by complement activation and leukocyte (mainly eosinophil and neutrophil) infiltration ([@bib43]). In contrast, autoantibodies appear to directly decrease the adhesive function of the basement membrane without initiating significant inflammation in the noninflammatory form of epidermolysis bullosa acquisita ([@bib20]). Unfortunately, further details of the pathomechanism of bullous pemphigoid and epidermolysis bullosa are poorly understood, and therefore, the therapeutic options are rather limited ([@bib17]).

A number of in vivo models mimic bullous pemphigoid or the inflammatory form of epidermolysis bullosa acquisita by using active or passive immunization against components of the dermal-epidermal junction in experimental animals ([@bib13]). The most widely used model relies on the passive immunization of mice with IgG antibodies against the immunodominant NC1 domain of C7 ([@bib26], [@bib46], [@bib47]). Because this intervention triggers substantial inflammation and inflammatory pathway components are critical to disease pathogenesis (see below), this model is believed to mimic the inflammatory but not the noninflammatory form of epidermolysis bullosa acquisita.

Animal models of bullous pemphigoid and epidermolysis bullosa acquisita have shown striking similarities between the pathomechanism of the two disease models. Critical components include activating Fc-receptors ([@bib18], [@bib44], [@bib46], [@bib55]), the alternative pathway of complement activation ([@bib23], [@bib28], [@bib46]) and myeloid cells such as neutrophils ([@bib5], [@bib24]). Our recent signaling studies showed complete protection of mice lacking three Src family kinases expressed in myeloid cells (Hck, Fgr and Lyn) from skin inflammation triggered by antibodies against C7 ([@bib21]), whereas mice lacking phosphatidylinositol 3-kinase β (PI3Kβ) ([@bib22]) or the CARD9 adapter protein ([@bib37]) were partially protected. Additional experiments pointed to a critical role for those molecules within the neutrophil compartment in all three cases.

Syk is a nonreceptor tyrosine kinase primarily expressed in cells of hematopoietic origin ([@bib33]). Syk is involved in signal transduction of a number of tyrosine kinase-coupled receptors including β~2~-integrins and various Fc-receptors ([@bib35], [@bib34], [@bib33], [@bib37]). Src family kinases are involved in Syk activation in most of those cases ([@bib21], [@bib35], [@bib30], [@bib33]). Hematopoietic or neutrophil-specific deletion of Syk protects mice from arthritis development in the K/B × N serum-transfer model ([@bib7], [@bib15]), and Syk has been proposed to be a potential target in rheumatoid arthritis and other autoimmune inflammatory diseases ([@bib10], [@bib33], [@bib54]). However, the role of Syk in autoimmune inflammatory skin diseases is still unclear.

The discussed findings and the lack of information on the role of Syk in autoimmune dermatitis prompted us to test the role of Syk in an in vivo model of the inflammatory form of epidermolysis bullosa acquisita in experimental mice. Our results indicate that Syk is critically involved in skin inflammation triggered by autoantibodies against C7, identifying Syk as a potential therapeutic target in epidermolysis bullosa acquisita and, possibly, other inflammatory skin diseases of similar pathomechanism.

Results {#sec2}
=======

Neutrophil activation by C7-containing immune complexes {#sec2.1}
-------------------------------------------------------

We have previously shown that immobilized human serum albumin (HSA)--anti-HSA immune complexes trigger robust activation of neutrophils ([@bib14]). To determine whether immune complexes containing dermal-epidermal junctional proteins can also activate neutrophils, we generated immobilized immune complexes using a His-tagged fragment of the immunodominant NC1 domain of murine C7 (His-C7) and rabbit polyclonal IgG (anti-C7) against the GST fusion protein of the same fragment ([@bib6], [@bib45]). Plating wild-type (WT) mouse neutrophils on such immobilized immune complexes triggered robust activation of the cells as measured by the release of superoxide anions ([Figure 1](#fig1){ref-type="fig"}a; *P* = 4 × 10^--6^). Neutrophil activation required both the antigen and the antibody components ([Figure 1](#fig1){ref-type="fig"}a). His-C7--anti-C7 immune complexes also triggered spreading of the cells over the immune complex-coated surface ([Figure 1](#fig1){ref-type="fig"}b).Figure 1**Type VII collagen-containing immune complexes trigger neutrophil activation and Syk phosphorylation through Src family kinases.** (**a**) Respiratory burst of WT mouse neutrophils plated on surfaces treated with His-C7 and/or anti-C7. (**b**) His-C7--anti-C7 immune complexes trigger spreading of WT neutrophils. (**c**) Specificity of the His-C7‒anti-C7- and HSA--anti-HSA-induced responses. (**d--e**) Src family kinases are essential for His-C7‒anti-C7 immune complex-triggered superoxide release and Syk-phosphorylation. Kinetic curves and graphs in **a**, **c**, and **d** show mean and standard error of the mean of 2 to 3 independent experiments. In panels **a** and **d**, control data points were subtracted. Panels **b** and **e** are representative of 2 to 3 independent experiments. See the text for actual *P*-values. Scale bar = 20 μm. 3 × SFK KO, *Hck*^--/--^*Fgr*^--/--^*Lyn*^--/--^; C7, collagen type VII; HSA, human serum albumin; IP, immunoprecipitation; KO, knockout; min, minute; WT, wild-type.

To test the antigen specificity of neutrophil activation, ELISA plates were coated with His-C7 or HSA, blocked, and then incubated with anti-C7 or anti-HSA antibodies. As shown in [Figure 1](#fig1){ref-type="fig"}c, neutrophils mounted a robust respiratory burst in the presence of matching antigen-antibody pairs (His-C7 with anti-C7 or HSA with anti-HSA; *P* = 8 × 10^--6^ and *P* = 1.9 × 10^--3^, respectively) but not when nonmatching antigen-antibody pairs were used.

Taken together, C7-containing immune complexes are able to specifically activate neutrophil functions.

Src family kinases mediate neutrophil respiratory burst and Syk activation by C7-containing immune complexes {#sec2.2}
------------------------------------------------------------------------------------------------------------

We have recently shown that the Src family kinases Hck, Fgr, and Lyn are critically involved in neutrophil activation triggered by HSA--anti-HSA immune complexes ([@bib21]). To test whether this also applies to C7-containing immune complexes, we tested the responses of *Hck*^--/--^*Fgr*^--/--^*Lyn*^--/--^ (3 × SFK knockout \[KO\]) neutrophils. As shown in [Figure 1](#fig1){ref-type="fig"}d, 3 × SFK KO neutrophils failed to release superoxide under such conditions.Figure 2**Characterization of WT and *Syk*^--/--^ bone marrow chimeras and their neutrophils.** (**a**) Flow cytometric analysis of the donor-specific CD45.2 epitope in peripheral blood neutrophils tested 4 weeks after BM transplantation. (**b**) Immunoblot analysis of Syk expression in various cell types from WT and *Syk*^‒/‒^ BM chimeras. (**c**) Circulating neutrophil (PMN) counts in WT and *Syk*^‒/‒^ chimeras. (**d**) Average neutrophil number isolated from the BM of the different chimeras. (**e**) Cell surface molecule expression of WT and *Syk*^‒/‒^ BM-isolated neutrophils. Panels **a**, **b**, and **e** are representative of 3 to 10 independent experiments. Graphs in panel **c** and **d** show mean and standard error of the mean from 9 to 11 mice. See the text for actual *P*-values. BM, bone marrow; PMN, polymorphonuclear cell; WT, wild-type.Figure 3**Syk is required for experimental epidermolysis bullosa acquisita.** Skin disease was triggered in WT or *Syk*^--/--^ bone marrow chimeras by anti-C7 antibodies and was followed by (**a**) photographing the heads, the trunks, and the ears and clinical assessment of (**b**) the body surface affected and (**c**) the overall disease severity. (**d**) Serum anti-C7 levels were tested by ELISA. (**e**) Hematoxylin and eosin stained ear histological sections are presented from WT and *Syk*^--/--^ chimeras. The right images were magnified from the pictures seen on the left. Original magnification ×10. (**a, e**) Representative images or (**b, c**) mean and standard error of the mean from 3 control and 12 to 13 anti-C7--treated mice per genotype from 3 independent experiments are shown. Panel **d** shows mean and standard error of the mean from 2 to 3 control and 9 to 11 anti-C7--treated mice from 2 independent experiments. See the text for actual *P*-values. Scale bar = 100 μm. C7, collagen type VII; OD, optical density; WT, wild-type.

Syk is a nonreceptor tyrosine kinase activated downstream of Src family kinases in several immunoreceptor-induced signaling pathways ([@bib8], [@bib33]). We next tested whether this is also true for neutrophil activation by C7-containing immune complexes. WT neutrophils plated on immobilized His-C7--anti-C7 immune complexes showed Syk phosphorylation (a measure of Syk activation), whereas no such response could be observed in 3 × SFK KO neutrophils ([Figure 1](#fig1){ref-type="fig"}e, and see the entire blots in [Supplementary Figure S1](#appsec1){ref-type="sec"} online).

Taken together, neutrophil activation by C7-containing immune complexes triggers Syk activation downstream of the Src family kinases Hck, Fgr, and Lyn.

Generation and characterization of *Syk*^--/--^ bone marrow chimeras {#sec2.3}
--------------------------------------------------------------------

These findings raised the possibility that Syk may also be involved in anti-C7 antibody-induced skin inflammation. Unfortunately, the perinatal lethality of genetically Syk-deficient (*Syk*^--/--^) animals ([@bib1], [@bib33], [@bib50]) did not allow us to test this in intact animals. To overcome that problem, we generated bone marrow chimeras lacking Syk only in their hematopoietic compartment (termed *Syk*^--/--^ bone marrow chimeras) by transplanting fetal liver cells of *Syk*^--/--^ fetuses into lethally irradiated WT recipients ([@bib35]). Control chimeras (termed WT bone marrow chimeras) were generated by parallel transplantation of *Syk*^+/+^ or *Syk*^+/--^ fetal liver cells. Differential expression of CD45 alleles in the donor (CD45.2) and the recipient (CD45.1) cells allowed identification of donor- and recipient-derived cells. As shown in [Figure 2](#fig2){ref-type="fig"}a, practically all peripheral blood neutrophils of WT or *Syk*^--/--^ bone marrow chimeras expressed the donor-derived CD45.2 allele, indicating complete repopulation of the hematopoietic compartment by donor-derived cells. In addition, Syk was present in lysates of freshly isolated neutrophils and platelets, as well as of bone marrow-derived macrophages and mast cells, from WT but not *Syk*^--/--^ bone marrow chimeras ([Figure 2](#fig2){ref-type="fig"}b). Therefore, we were able to replace the WT hematopoietic compartment of the recipient mice with donor-derived (e.g., *Syk*^--/--^) cells.

We did not observe any difference in circulating neutrophils numbers between WT and *Syk*^--/--^ bone marrow chimeras ([Figure 2](#fig2){ref-type="fig"}c) (*P* = 0.69), and similar numbers of bone marrow neutrophils could be isolated from chimeras of the two genotypes ([Figure 2](#fig2){ref-type="fig"}d) (*P* = 0.37). In addition, *Syk*^--/--^ neutrophils expressed normal levels of the neutrophil maturation marker Ly6G, the β~2~ integrin component CD18, the major neutrophil chemokine receptor CXCR2, and the Fc-receptors FcγRII/III and FcγRIV ([Figure 2](#fig2){ref-type="fig"}e). Therefore, the *Syk*^--/--^ mutation did not interfere with the generation or maturation of neutrophils or with the expression of critical cell surface receptors.

*Syk*^--/--^ bone marrow chimeras are completely protected from skin inflammation triggered by anti-C7 antibodies {#sec2.4}
-----------------------------------------------------------------------------------------------------------------

We next subjected WT and *Syk*^--/--^ bone marrow chimeras to repeated subcutaneous injection of anti-C7 or normal rabbit IgG/phosphate buffered saline as a model of inflammatory autoimmune blistering skin diseases ([@bib46]). Our previous studies have indicated a critical role for the Fc portion of the pathogenic antibodies in this model ([@bib46]). As shown in [Figure 3](#fig3){ref-type="fig"}a, WT chimeras treated with anti-C7 antibodies developed significant signs of skin inflammation at several body areas, ranging from loss of the superficial layer of the skin (most prominent in the buccal/periorbital area) to severe inflammation and scarring at the most severely affected places (most prominent on the ears). *Syk*^--/--^ bone marrow chimeras were completely protected from development of all those skin inflammatory changes ([Figure 3](#fig3){ref-type="fig"}a).

Quantification of the overall skin changes showed that the percentage of the affected body surface area gradually increased over the assay period in WT chimeras, whereas no signs of the disease could be observed in *Syk*^--/--^ chimeras ([Figure 3](#fig3){ref-type="fig"}b) (*P* = 0.022). Similarly, the overall clinical score also gradually increased during the assay period in WT chimeras without any signs of the disease in *Syk*^--/--^ chimeras ([Figure 3](#fig3){ref-type="fig"}c) (*P* = 6.0 × 10^--3^).

A possible explanation for these findings could be that the *Syk*^--/--^ mutation affects the metabolism of the injected pathogenic antibodies. However, no differences in circulating anti-C7 antibody titers could be observed between the WT and *Syk*^--/--^ genotypes ([Figure 3](#fig3){ref-type="fig"}d) (*P* = 0.69).

We next tested skin inflammation by histological analysis of the ear tissue. As shown in [Figure 3](#fig3){ref-type="fig"}e, anti-C7 antibody treatment triggered substantial thickening of the ear of WT chimeras with prominent leukocyte infiltration. However, no such inflammatory changes could be observed in *Syk*^--/--^ bone marrow chimeras.

Taken together, the *Syk*^--/--^ mutation blocks the capability of anti-C7 antibodies to trigger skin inflammation both at the macroscopic and microscopic levels, without affecting their removal from the circulation.

The *Syk*^--/--^ mutation blocks neutrophil recruitment without affecting the intrinsic migratory capacity of neutrophils {#sec2.5}
-------------------------------------------------------------------------------------------------------------------------

The inflammatory form of epidermolysis bullosa acquisita is characterized by a significant influx of granulocytes (eosinophils and neutrophils), which are likely involved in the inflammation process ([@bib43]). As shown in [Figure 4](#fig4){ref-type="fig"}a, anti-C7 antibodies triggered dramatic influx of neutrophils to the ear of WT bone marrow chimeras, which appears to be a peculiarity of this mouse model (compared with the dominant infiltration by eosinophils in the inflammatory form of human epidermolysis bullosa acquisita). In agreement with the histological pictures ([Figure 3](#fig3){ref-type="fig"}e), no such accumulation of neutrophils could be observed in *Syk*^--/--^ chimeras ([Figure 4](#fig4){ref-type="fig"}a) (*P* = 7.7 × 10^--3^).Figure 4**Syk is essential for forming the inflammatory environment.** (**a**) The accumulation of neutrophils in the ear upon anti-C7 injection was determined by flow cytometry. (**b, c**) Mixed bone marrow chimeras with CD45.1-expressing WT and CD45.2-expressing WT or *Syk*^--/--^ hematopoietic cells were injected with anti-C7 antibodies and neutrophil accumulation was determined by flow cytometric analysis. In panel **b**, each dot represents an individual ear, and panel **c** shows the relative migration of WT and *Syk*^--/--^ neutrophils. (**d--f**) Decreased in vivo CXCL2, IL-1β, and LTB~4~ levels in the ears of Syk-deficient chimeras. Graphs represent mean and standard error of the mean from (**a**) 3 to 5 or (**c**) 2 to 6 mice and (**d--f**) 3 to 4 control or 5 to 7 anti-C7--treated mice per group from 2 to 3 independent experiments. See the text for actual *P*-values. C7, collagen type VII; LTB~4~, leukotriene B~4~; PMN, polymorphonuclear cell; WT, wild-type.

The simplest explanation for these findings would be an intrinsic migration defect of *Syk*^--/--^ neutrophils. However, we previously reported normal migration of *Syk*^--/--^ neutrophils toward various proinflammatory agonists both under in vitro and in vivo conditions ([@bib35], [@bib34]). To test this question in anti-C7--induced skin inflammation, we generated mixed bone marrow chimeras carrying leukocytes (including neutrophils) from both CD45.1-expressing WT and CD45.2-expressing WT or *Syk*^--/--^ bone marrow cells. Such chimeras developed signs of inflammation because of the presence of WT cells. Comparative flow cytometric analysis of CD45.1/2 expression in the inflammatory infiltrate and the peripheral blood then allowed us to compare the migration of WT and *Syk*^--/--^ neutrophils within the same animal. The percentage values for the peripheral blood and ear samples are presented in [Figure 4](#fig4){ref-type="fig"}b, whereas the relative migratory capacity of the CD45.2 (WT or *Syk*^--/--^) cells relative to the CD45.1 (WT) reference cells (calculated based on the data in [Figure 4](#fig4){ref-type="fig"}b) is shown in [Figure 4](#fig4){ref-type="fig"}c. As expected, the percentage of WT CD45.2 cells was comparable in the peripheral blood and the inflamed ear in the chimeras transplanted with cells from two WT donors (WT:WT chimeras) ([Figure 4](#fig4){ref-type="fig"}b and c). The percentage of *Syk*^--/--^ CD45.2 cells in the inflamed ear tissue was also similar to that in the peripheral blood in WT:*Syk*^--/--^ chimeras ([Figure 4](#fig4){ref-type="fig"}b), and the calculated relative migration of *Syk*^--/--^ cells was similar to, or even higher than, that of WT cells ([Figure 4](#fig4){ref-type="fig"}c) (*P* = 4.4 × 10^--6^). Those results indicate that *Syk*^--/--^ neutrophils are intrinsically capable of migrating to the site of inflammation, arguing against an intrinsic migration defect in *Syk*^--/--^ neutrophils.

Taken together, although neutrophils failed to accumulate in the ear of anti-C7 antibody-treated *Syk*^--/--^ bone marrow chimeras, this was not due to an intrinsic migration defect of *Syk*^--/--^ neutrophils, because those cells were able to accumulate at the site of inflammation when WT cells were also present in mixed bone marrow chimeras.

The *Syk*^--/--^ mutation blocks the accumulation of proinflammatory mediators in vivo {#sec2.6}
--------------------------------------------------------------------------------------

An alternative explanation for the abrogation of neutrophil accumulation in *Syk*^--/--^ chimeras ([Figure 4](#fig4){ref-type="fig"}a) is that Syk deficiency may interfere with the development of a proper inflammatory (chemoattractant) microenvironment. As shown in [Figure 4](#fig4){ref-type="fig"}d, systemic administration of anti-C7 antibodies dramatically increased tissue levels of CXCL2 (MIP-2) in the ear of WT but not *Syk*^--/--^ bone marrow chimeras (*P* \< 10^--17^). Similarly, hematopoietic deficiency of Syk abrogated the accumulation of the proinflammatory cytokine IL-1β ([Figure 4](#fig4){ref-type="fig"}e) (*P* = 1.6 × 10^--7^). Moreover, anti-C7 antibodies also moderately increased the level of the lipid mediator leukotriene B~4~ (LTB~4~) (a major neutrophil chemoattractant in various inflammatory conditions) in WT but not *Syk*^--/--^ bone marrow chimeras ([Figure 4](#fig4){ref-type="fig"}f) (*P* = 0.038).

Taken together, hematopoietic deficiency of Syk somehow prevented the accumulation of various proinflammatory agonists at the site of inflammation, likely leading to the defective accumulation of *Syk*^--/--^ neutrophils and subsequent protection from clinical disease.

*Syk*^--/--^ neutrophils fail to respond to C7-containing immune complexes in vitro {#sec2.7}
-----------------------------------------------------------------------------------

Because neutrophils are capable of releasing various chemokines, cytokines, and lipid mediators ([@bib21], [@bib37], [@bib48]), we hypothesized that the discussed in vivo findings may be due to defective responses of *Syk*^--/--^ neutrophils to C7-containing immune complexes. Indeed, *Syk*^--/--^ neutrophils failed to release superoxide ([Figure 5](#fig5){ref-type="fig"}a) (*P* = 8.6 × 10^--4^) or spread over the adhesive surface ([Figure 5](#fig5){ref-type="fig"}b) when plated on immobilized His-C7--anti-C7 immune complexes. In addition, WT neutrophils released large amounts of both CXCL2 and LTB~4~, whereas no such responses could be observed in *Syk*^--/--^ samples ([Figure 5](#fig5){ref-type="fig"}c and d) (*P* = 3.8 × 10^--10^ and 1.1 × 10^--16^, respectively). Those results suggest that Syk is indispensable for neutrophil activation by C7-containing immune complexes, explaining the defective development of an in vivo inflammatory environment in *Syk*^--/--^ bone marrow chimeras.Figure 5**Syk is required for neutrophil responses on immobilized His-C7‒anti-C7 immune complexes.** (**a**) Respiratory burst, (**b**) cell spreading, (**c**) CXCL2, and (**d**) LTB~4~ release of WT and *Syk*^‒/‒^neutrophils. Curves in panel **a** show mean and standard error of the mean of 3 independent experiments; control data points were subtracted. Panel **b** is representative of 3 independent experiments. Graphs in **c** and **d** show mean and standard error of the mean from 3 independent experiments. See the text for actual *P*-values. Scale bar = 40 μm. C7, collagen type VII; His-C7, His-tagged fragment of the immunodominant NC1 domain of murine C7; LTB~4~, leukotriene B~4~; min, minute; WT, wild-type.

Discussion {#sec3}
==========

Here we report that the Syk tyrosine kinase is indispensable for an in vivo model of the inflammatory form of epidermolysis bullosa acquisita in experimental mice. This study raises the possibility that Syk may be a suitable therapeutic target in that disease and, possibly, in other diseases with a similar pathogenesis.

Syk has diverse biological functions ([@bib33]), primarily by mediating signaling from immunoreceptors such as Fc-receptors. Fc-receptors play a critical role in mouse models of bullous pemphigoid and the inflammatory form of epidermolysis bullosa acquisita ([@bib18], [@bib44], [@bib46], [@bib55]). Together with our studies on the role of Src family kinases ([@bib21]) and CARD9 ([@bib37]), our experiments suggest that anti-C7--induced skin inflammation is mediated by Syk linking Fc-receptor--mediated activation of Src family kinases to downstream signaling through the CARD9 adapter protein. This is reminiscent of signal transduction in K/B × N serum transfer arthritis and recognition of fungal pathogens ([@bib12]).

In agreement with other studies on neutrophil function ([@bib38], [@bib29]), our results suggest an important role for neutrophils in certain inflammatory autoimmune subepidermal blistering skin disease models. Our results of defective in vivo recruitment of *Syk*^--/--^ neutrophils despite apparently normal intrinsic migratory capacity ([Figure 4](#fig4){ref-type="fig"}a--c) and the defective accumulation of neutrophil-attracting proinflammatory mediators (CXCL2 and LTB~4~) in vivo ([Figure 4](#fig4){ref-type="fig"}d and f) and in in vitro neutrophil assays ([Figure 5](#fig5){ref-type="fig"}c and d) suggest that the principal role of Syk is to promote feedback amplification loops through proinflammatory mediator release by neutrophils ([@bib39]). Although we cannot exclude the role of Syk expression in another cell type, neutrophil-specific deletion of Syk completely protected mice from anti-C7--induced skin pathology (Németh and Mócsai, unpublished observation), indicating the central role for neutrophil-derived Syk in the disease process.

Besides identifying Syk as a critical player in autoantibody-induced skin inflammation, our results also raise a number of questions. What is the role of Syk in the initial immunization phase of autoimmune bullous skin diseases or the very first steps of anti-C7--induced skin inflammation before the initiation of the neutrophil-mediated feedback amplification process? Would it be possible to document differential chemokine gene expression of WT and *Syk*^--/--^ neutrophils in mixed bone marrow chimeras? Do our conclusions also apply to other autoimmune subepidermal blistering skin diseases where the autoantigen is other than C7 or where the inflammatory component is less pronounced? How much can we extrapolate our findings on mouse models to human autoimmune and other inflammatory skin diseases? Those and other questions need to be addressed by future follow-up studies.

Parallel to our own study initiated by the relationship between Src family kinases and Syk ([@bib4], [@bib9], [@bib21]), another study also identified Syk as a core signaling hub in the inflammatory form of epidermolysis bullosa acquisita (Ralf Ludwig, unpublished observations). Although both studies conclude that Syk is critical for disease development, they also complement each other by addressing different additional aspects, such as additional signaling and mechanistic experiments in this paper and bioinformatics and pharmacological aspects in the other study.

The pharmacological therapy of bullous pemphigoid and epidermolysis bullosa acquisita still relies on rather nonspecific immunosuppressive and anti-inflammatory agents. We have identified Syk as a critical component of autoantibody-induced skin inflammation in experimental mice. Although there are clear differences between our mouse model and the corresponding human disease(s) (passive vs. active immunization and neutrophils vs. eosinophils dominating the inflammatory infiltrate, respectively), we believe that our mouse studies relatively closely mimic important aspects of human pathology. Syk has emerged as a potential therapeutic target in other autoimmune inflammatory diseases such as rheumatoid arthritis, as well as in Syk-dependent hematologic malignancies ([@bib10]). Although fostamatinib, the first Syk inhibitor reaching clinical development, raised safety concerns likely related to its poor specificity ([@bib2], [@bib11], [@bib41], [@bib53]), there is a large effort from the pharmaceutical industry to develop much more specific Syk inhibitors ([@bib40], [@bib51]). Our results suggest that such Syk-specific inhibitors may be suitable for the pharmacological control of certain inflammatory autoimmune subepidermal blistering skin diseases such as the inflammatory form of epidermolysis bullosa acquisita or, possibly, the mechanistically related bullous pemphigoid.

Materials and Methods {#sec4}
=====================

Animals {#sec4.1}
-------

Mice carrying a deleted *Syk* allele (*Syk*^tm1Tyb^, referred to as *Syk*^--^) were from Victor Tybulewicz ([@bib50]) and kept in heterozygous form. Recipients carrying the CD45.1 allele on the C57BL/6 genetic background (B6.SJL-*Ptprc*^a^ mice from the Jackson Laboratory, Bar Harbor, ME) were lethally irradiated by 11 Gy from a ^137^Cs source using a Gamma-Service Medical D1 irradiator (Gamma-Service Medical GmbH, Leipzig, Germany) and then injected intravenously with fetal liver cells from *Syk*^--/--^ and control fetuses obtained from timed mating of *Syk*^+/--^ carriers ([@bib15], [@bib35]). *Hck*^tm1Hev/tm1Hev^*Fgr*^tm1Hev/tm1Hev^*Lyn*^tm1Sor/tm1Sor^ triple KO mice (referred to as *Hck*^--/--^*Fgr*^--/--^*Lyn*^--/--^ or 3 × SFK KO mice) were described previously ([@bib21], [@bib27]). Mice were kept in individually sterile ventilated cages (Tecniplast, Buguggiate, Italy) in a conventional facility. All animal experiments were approved by the Animal Experimentation Review Board of the Semmelweis University.

Autoantibody-induced skin blistering model {#sec4.2}
------------------------------------------

The murine model of the inflammatory form of human epidermolysis bullosa acquisita was triggered by systemic administration of antibodies against C7, which triggers skin inflammation through the antibody Fc portions ([@bib46]). Rabbits were immunized with a GST fusion protein containing a fragment of the immunodominant NC1 domain of murine C7 (GST-C7), followed by total IgG preparation (anti-C7) ([@bib6], [@bib46]). The reactivity of the antibody preparation was tested with a His-tagged murine type VII collagen fragment (His-C7) ([@bib6]). Normal rabbit IgG (Sigma-Aldrich, St. Louis, MO) or phosphate buffered saline (Thermo Fisher, Waltham, MA) was used as control.

Twelve milligrams of pathogenic or control IgG was injected subcutaneously under isoflurane anesthesia on days 0, 2, 4, 6, and 8 (60 mg total IgG/mouse). Disease onset and progression were followed by clinical assessment, and quantitative scoring was based on the specific dermatological abnormalities and the size of the affected skin area ([@bib21], [@bib37], [@bib46]). Serum anti-C7 levels were determined by ELISA using His-C7. For histological analysis, mice were killed on day 8 (when no open wounding had occurred), and their ears were fixed in paraformaldehyde, dehydrated, embedded in paraffin, sectioned at 9 μm thickness, and stained with hematoxylin and eosin.

In vivo analysis of neutrophil accumulation {#sec4.3}
-------------------------------------------

WT and Syk-deficient bone marrow chimeras were injected with control or pathogenic IgG. On days 8 through 10, mice were killed, and their ears were removed. The samples were digested with Liberase II (Roche, Basel, Switzerland) ([@bib52]). Single-cell suspensions were obtained, and neutrophil numbers were determined by flow cytometry on the basis of their forward and side scatter characteristics and Ly6G-positivity (clone 1A8, BD Biosciences, San Jose, CA).

In vivo neutrophil migration {#sec4.4}
----------------------------

A competitive migration assay in mixed bone marrow chimeras was used to assess in vivo migration of neutrophils ([@bib16], [@bib21], [@bib35]). WT (C57BL/6) or *Syk*^--/--^ bone marrow cells (carrying the CD45.2 allele) were mixed at varying ratios with bone marrow cells from congenic mice expressing CD45.1 on the C57BL/6 genetic background. The cell suspension was injected intravenously into lethally irradiated CD45.1-expressing recipient mice. After bone marrow repopulation, the chimeras were subjected to experimental epidermolysis bullosa acquisita, and their ears were digested (before any open wounds occurred). The percentage of CD45.2-expressing neutrophils was analyzed by flow cytometry with staining for Ly6G and CD45.2 (clone 104, BD Biosciences).

Relative migration of the CD45.2-positive neutrophils (relative to the CD45.1-expressing WT cells) was calculated as described ([@bib16]).

Isolation and activation of neutrophils {#sec4.5}
---------------------------------------

Mouse neutrophils were isolated from the bone marrow by Percoll (GE Healthcare, Chicago, IL) gradient centrifugation ([@bib34]). Neutrophil assays were performed at 37 °C in HBSS (GE Healthcare, Little Chalfont, UK) supplemented with 20 mmol/L HEPES, pH 7.4 or in DMEM (Sigma-Aldrich). Cell surface molecule expression was detected by anti-Ly6G-phycoerythrin (clone 1A8), anti-CD18-biotin (clone C71/16), anti-CXCR2-phycoerythrin (clone \#242216, R&D Systems, Minneapolis, MN), anti-FcγRII/III (clone 2.4G2) and anti-FcγRIV-phycoerythrin (clone 9E9) antibodies. Where required, secondary staining with Streptavidin-phycoerythrin or mouse anti-rat--FITC (clone MRK-1) was performed. If not otherwise stated, the antibodies were from BD Biosciences.

Immobilized immune complex-coated surfaces were obtained by binding His-C7 at 20 μg/ml to Nunc MaxiSorp F96 plates (Thermo Fisher) or tissue culture dishes, blocked, and then treated with anti-C7 at a 1:10 dilution, otherwise as described ([@bib14]). HSA and anti-HSA immune complexes were generated as described ([@bib14]).

For the analysis of mediator release, neutrophils were stimulated for 1 (LTB~4~) or 6 (cytokines) hours, and supernatants were collected for further analysis ([@bib21], [@bib37]). Superoxide release was followed by a cytochrome c reduction test ([@bib36]).

Isolation of other cell types {#sec4.6}
-----------------------------

Platelets were isolated from peripheral blood by mild centrifugation in the presence of heparin. Mast cells were cultured from the bone marrow by murine IL-3 and stem cell factor (both from PeproTech, Rocky Hill, NJ). Macrophages were obtained by culturing bone marrow cells in the presence of recombinant murine macrophage colony-stimulating factor from a conditioned medium ([@bib19]).

Analysis of inflammatory mediators {#sec4.7}
----------------------------------

The removed ears were either crushed under liquid nitrogen and lysed by a Triton-based buffer or were cut into small pieces and were digested. The release of mediators was tested from the ear lysates, the cell-free supernatants of digested samples, or of in vitro stimulated neutrophils. The levels of CXCL2, IL-1β, and LTB~4~ were tested by commercial ELISA kits (R&D Systems).

Biochemical studies {#sec4.8}
-------------------

For analysis of Syk phosphorylation, neutrophils were plated on immune complex-covered 6-cm tissue culture dishes, incubated for 10 minutes at 37 °C, and lysed on ice (adherent and nonadherent cells combined) ([@bib21]). Immunoprecipitation was performed by an anti-Syk antibody (5F5, BioLegend, San Diego, CA) followed by capturing with Protein G-Agarose (Invitrogen, Waltham, MA) ([@bib32], [@bib31], [@bib30], [@bib37]). Whole-cell lysates from the same experiments were used as controls.

Samples were run on SDS-PAGE and immunoblotted using antibodies against phosphotyrosine (clone 4G10, Merck Millipore, Billerica, MA), Syk (N19, Santa Cruz Biotechnology, Dallas, TX), or β-actin (clone AC-74, Sigma-Aldrich) followed by incubation with peroxidase-labeled secondary antibodies (GE Healthcare). The signal was developed using the enhanced chemiluminescence system (GE Healthcare) and exposed to X-ray films.

Presentation of the data and statistical analysis {#sec4.9}
-------------------------------------------------

Experiments were performed the indicated number of times. Quantitative graphs and kinetic curves show mean and standard error of the mean from all independent in vitro experiments or from all individual mice from the indicated number of experiments. Statistical analyses were carried out using one- or two-way (factorial) analysis of variance (with treatment and genotype being the two independent variables). Area under the curve was used for statistical analysis in kinetic measurements. *P*-values below 0.05 were considered statistically significant.
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